Levetiracetam Altan Pharma

Levetiracetam, the active ingredient in Levetiracetam Altan Pharma, is an antiepileptic presented as a intravenous solution for intravenous use. It treats partial‑onset, myoclonic, and primary generalized tonic‑clonic seizures in patients requiring adjunctive therapy.

GNH USA supplies Levetiracetam Altan Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic medication used as adjunctive therapy for several seizure types.

- Partial‑onset seizures: reduces seizure frequency when added to existing therapy. - Myoclonic seizures: provides additional seizure control in patients with myoclonic epilepsy. - Primary generalized tonic‑clonic seizures: helps achieve better seizure control as an adjunct.

Levetiracetam may be associated with a range of adverse reactions, ranging from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate head pain. - Irritability: mood changes or increased agitation.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood or behavior changes: depression, suicidal thoughts, or aggression. - Blood disorders: neutropenia, thrombocytopenia, or anemia.

When prescribing Levetiracetam, clinicians should consider several safety and handling precautions. - Renal function: adjust use in patients with impaired renal clearance. - Pregnancy: limited data; evaluate risk‑benefit before use. - Concomitant CNS depressants: monitor for enhanced sedation. - Psychiatric history: watch for mood alterations or aggression. - Drug interactions: review concomitant antiepileptic and enzyme‑inducing agents. - Store at ambient temperature: keep below 25 °C, protect from moisture and light, retain in original packaging.

Levetiracetam can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenytoin: may decrease levetiracetam exposure. - Phenobarbital: potential reduction in levetiracetam concentration.

Moderate Interactions (Monitor Closely): - Other antiepileptics (e.g., valproate): monitor for additive CNS effects. - CNS depressants (e.g., benzodiazepines): watch for increased sedation. - Alcohol: may enhance drowsiness.